Narcolepsy With Cataplexy
15
1
1
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
47%
7 trials in Phase 3/4
60%
6 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (15)
A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
Decreasing Nightmares in Adults With Narcolepsy
Clarithromycin Mechanisms in Hypersomnia Syndromes
Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period
Awareness and Self-Compassion Enhancing Narcolepsy Treatment
Narcolepsy Nightmare Study
A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1
An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy
Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes
Xyrem and Brain Dopamine in Narcolepsy
A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy'
Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy
A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy
Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)